Related Experiment Video
Updated: May 25, 2026
07:55
Imaging the Intracellular Trafficking of APP with Photoactivatable GFP
Published on: October 17, 2015
Membrane trafficking pathways in Alzheimer's disease
Lawrence Rajendran1, Wim Annaert
1Systems and Cell Biology of Neurodegeneration, Division of Psychiatry Research, University of Zurich, August-Forel Str. 1, Zurich 8008, Switzerland. rajendran@bli.uzh.ch
Traffic (Copenhagen, Denmark)
|January 25, 2012
Summary
Membrane trafficking of amyloid precursor protein (APP) and tau is crucial in Alzheimer's disease (AD) pathogenesis. Understanding these cellular processes offers new therapeutic avenues for AD.
Area of Science:
- Cell Biology
- Neuroscience
- Molecular Biology
Background:
- Membrane proteins, including amyloid precursor protein (APP), undergo continuous trafficking within cells.
- Alzheimer's disease (AD) involves APP processing and tau pathology, traditionally studied separately.
- Recent research suggests a physiological connection between amyloid-beta (Aβ) toxicity and tau pathology.
Purpose of the Study:
- To review the role of membrane trafficking in APP processing and its relevance to Alzheimer's disease.
- To explore the emerging connection between Aβ toxicity and tau pathology.
- To discuss the therapeutic potential of targeting membrane trafficking pathways in AD.
Main Methods:
- Review of current literature on membrane protein trafficking in neurons.
- Analysis of molecular mechanisms regulating APP processing and sorting.
- Integration of findings on Aβ and tau biology.
Main Results:
- Identification of regulatory sorting mechanisms, protein interactions, and lipid microenvironments governing APP processing.
- Emerging evidence linking APP trafficking and Aβ production to tau pathology.
- Highlighting the potential of membrane trafficking as a therapeutic target.
Conclusions:
- Membrane trafficking is a critical, unifying factor in Alzheimer's disease pathogenesis.
- Targeting cellular trafficking pathways presents a promising strategy for novel AD therapies.
More Related Videos
06:41Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
Published on: January 10, 2025
15:04Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils
Published on: September 28, 2019
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:44Introduction to Membrane Traffic
The ER, Golgi apparatus, endosomes, and lysosomes work in tandem to modify, sort, and package proteins and lipids. An integrated membrane trafficking network facilitates the back and forth shuttling of molecules within different organelles in the same cell or across the cell membrane.
The transport of soluble and membrane proteins is mediated by transport vesicles that collect cargo from one cellular compartment and deliver it to another by fusing with the target organelle membrane. The Rab...
The transport of soluble and membrane proteins is mediated by transport vesicles that collect cargo from one cellular compartment and deliver it to another by fusing with the target organelle membrane. The Rab...